Acrosome Reaction Induction Prior to ICSI (RA-ICSI)

October 15, 2015 updated by: Assistance Publique - Hôpitaux de Paris

Improvement of the Post ICSI Pregnancy Outcome by Induction of the Acrosome Reaction Prior to ICSI

Introduction To get through the egg vestment and fertilize the oocyte, the spermatozoon uses its acrosomal enzymes. When Intracytoplasmic sperm microinjection (ICSI) is performed, the acrosomal enzymes are introduced with the spermatozoa inside the ooplasme.

The fate of these enzymes, that normally never enter the oocyte, is not known. But they impair the embryo development.

Indeed, although the ICSI outcome is satisfactory in humans, a series of studies in many species (mouse, hamster, cattle, and horse) demonstrate the deleterious effects of the introduction of acrosomal material in the oocyte cytoplasm, on embryo and fetal development. These studies have also shown two things:

  • The bigger the acrosome, the more deleterious are the effects of their introduction into the egg.
  • And that the induction of the acrosome reaction (AR) prior to ICSI significantly improves embryonic development and the number of babies born after embryo transfer as it is the case in the mouse. The microinjection of acrosome reacted sperm increases from 40 to 70 % the percentage of pups born per embryo transferred.

Hypothesis :

It is possible to improve ICSI outcome, in terms of babies born in human, by induction of the AR prior to microinjection.

After studying several techniques, we choose a physiologic technique for acrosome induction.

The induction of acrosome reaction prior to ICSI should improve in utero fetal development and decrease the rate of miscarriage and pregnancy arrest.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

  1. Introduction Intracytoplasmic sperm microinjection (ICSI) produces 70% of fertilized oocytes and zygotes which mostly develop normally. To perform ICSI, a spermatozoon is taken from a sperm suspension after gradient migration. It is then immobilized by breaking its flagellum using a micropipette, and introduced into the oocyte cytoplasm.

    The rate of spontaneous acrosome reaction in humans is less than 20 %. Two studies on the percentage of acrosome reacted and immobilized sperm showed that 95% of them have a destabilization of the membrane but only 17.8% of them had made a full RA. In other words, when we microinjected 10 spermatozoa, only 2 of them are completely rid of their acrosome material. All others are introduced into the oocyte with acrosomal material. But this material does not normally enter the oocyte since the acrosome reaction is a prerequisite to the passage of the zona pellucida that surrounds the egg .

    The importance of using an acrosome-reacted spermatozoon for the success of ICSI has been previously highlighted in several animal species. It has been demonstrated that the induction of the acrosome reaction in mice lead to higher fertilization rates (from 30% to about 60 % ) . It is similar, in the rabbit and horses . Kimura et al. also reported that mouse oocytes injected with acrosome-intact rabbit and hamster sperm exhibited a nuclear activation and cessation of embryonic development without reaching the two-cell stage. This "cytotoxicity" of the same sperm disappears when they are released from their acrosomes before injection. In another study, the detrimental effect on oocyte survival of the presence of the acrosome during the injection of sperm heads was demonstrated in the golden hamster. All oocytes microinjected with acrosome-intact sperm were dead, while only those injected with acrosome reacted sperm have not only survived, but have also developed to the stage of two pronucleus in 79 % of cases and helped to get live births ( 19%).

    The team of Yanagimachi reported a study on the potentially dangerous effect of the incorporation of the sperm acrosome of different species within mouse oocytes. According to these authors, harmful components would probably be the enzymes such as trypsin-like acrosine and hyaluronidase, since their injection mimicked the effects of ICSI with acrosome-intact sperm. In the same study, it was confirmed that the toxic effects were correlated with the size of the acrosome and therefore the contents of protease enzymes.

    The toxic effects of the acrosome and its contents have been described explicitly by Morozumi and Yanagimachi. It induces deformation of the oocyte with an irregular appearance, edema or cytolysis with a pseudo-vacuolated cytoplasm appearance. Furthermore, it has been established that the damage caused by exogenous or acrosomales enzymes were correlated with oocyte cytoskeleton disruption through an aberrant accumulation of microtubules in the cortex of the oocyte.

    In addition to the morphological and ultrastructural alterations in the oocyte, the incorporation of the acrosome may result in a lack of nuclear activation of the oocyte. Kasai et al. reported that the completion of oocyte meiosis occur faster if the sperm was released from the acrosome. Similarly, an increase in fertilization rate after ICSI with acrosome reacted sperm was observed in pigs. The study by Morozumi et al. also demonstrated that the induction of the acrosome reaction of sperm from several species prior to ICSI resulted in an acceleration of oocyte activation, which was manifest in human spermatozoa. This was evidenced by the significant differences between the profiles of calcium oscillations after ICSI with acrosome-intact or acrosome-reacted sperm. Calcium waves recorded in oocytes injected with acrosome-reacted spermatozoa were characterized by an early onset and amplitude and a higher frequency. In contrast, the calcium response was abnormally delayed in oocytes injected with acrosome-intact sperm.

    Thus, altered calcium oscillations, the "key" oocyte activation signals during ICSI, is the cause of abnormal pre-implantation embryo development to the blastocyst stage. Indeed, the proportion of live healthy mice births is increased from 40% to 71%, when intact or acrosome-reacted sperm are microinjected, respectively .

    These same studies have also shown two things:

    • The introduction of acrosomal material is more harmful when the quantity is large compared to the oocyte volume. There is therefore interest in systematically reducing the amount of material introduced into the oocyte cytoplasm to improve embryonic development.
    • The second thing is that the induction of the acrosome reaction before ICSI greatly improves embryonic development and therefore the number of babies born from embryo transfer.

    Although ICSI in human gives very satisfactory results, the rate of infants obtained by embryo is lower than after IVF embryos transfer. Hence, there is a possibility of improving the results of ICSI by induction of the acrosome reaction prior to microinjection.

    After several studies we used incubation of spermatozoa with the follicular fluid (FF) of the partner to induce the spermatozoa acrosome reaction (Karim Rahal, 2011 Master Thesis 2). FF is indeed a potent inducer of the AR. There is no problem of traceability since the FF of the patient is used only for the sperm of her husband. This technic can be applied to the poorest semen. Finally, the technique is used in a very easy routine, since the follicular fluid is always recovered during oocyte retrieval and thus available.

  2. Hypothesis A preliminary study was run in human on microinjection of spermatozoa that were selected for their acrosomal status by birefringence microscopy. It showed that it improves the implantation rate from 24,4 % to 39 % . We therefore hypothesize that the improvement in the implantation rate of embryos obtained by ICSI after acrosomal induction as well as the reduction of miscarriage rate may result in improved clinical pregnancy outcome and birth rates of about 10 %.

Study Type

Interventional

Enrollment (Anticipated)

620

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Paris, France, 75014
        • Hôpital Cochin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 43 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Couples involved in an ICSI program
  • First attempt only
  • Cohort with at least 6 oocytes

Exclusion Criteria:

  • No social security number
  • No signed consent form
  • Surgically retrieved sperm

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: micoinjection according to classical protocole
incubation of sperm in incubation medium
Other: capacitation in incubation medium prior to ICSI
Experimental: incubation in follicular fluid
incubation of sperm in follicular fluid prior to microinjection
Other: Acrosome Reaction induction

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
number of early pregnancy termination
Time Frame: 9 months
9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

Agence de La Biomédecine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2014

Primary Completion (Anticipated)

January 1, 2016

Study Completion (Anticipated)

October 1, 2016

Study Registration Dates

First Submitted

October 7, 2014

First Submitted That Met QC Criteria

October 21, 2014

First Posted (Estimate)

October 22, 2014

Study Record Updates

Last Update Posted (Estimate)

October 16, 2015

Last Update Submitted That Met QC Criteria

October 15, 2015

Last Verified

October 1, 2015

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2011-A01376-35

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy Outcome

Clinical Trials on capacitation in incubation medium prior to ICSI

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe